TIM-3 was not acting as a brake on NK cells. Instead, it was functioning as an accelerator.
In the shadow of a tick-borne hemorrhagic fever that kills up to half its victims, researchers have discovered that the immune system's own frontline defenders may be accelerating death rather than preventing it. A study published in PLOS Neglected Tropical Diseases finds that natural killer cells bearing a protein called TIM-3 enter a state of dangerous hyperactivation in fatal cases of severe fever with thrombocytopenia syndrome, flooding the body with inflammatory signals that compound the virus's damage. The work offers both a prognostic beacon — serum Galectin-9 — and a therapeutic hypothesis: that quieting the immune system's excess, rather than amplifying its force, may be the path toward survival.
- SFTS kills between 12 and 50 percent of those infected, and until now the role of natural killer cells in driving that mortality has been poorly understood.
- TIM-3-positive NK cells were found in nearly 95 percent of circulating NK cells in patients who died, compared to 74.5 percent in survivors — and these cells were armed and firing, loaded with cytotoxic proteins that damaged the host as much as the virus.
- Blocking TIM-3 with an antibody in lab experiments reduced inflammatory cytokines and cytotoxic output, revealing that TIM-3 functions as an accelerator of immune destruction in SFTS, not a brake.
- Serum Galectin-9 emerged as a validated early warning signal across an independent cohort of 104 patients, capable of flagging high-risk individuals within hours of admission before organ failure becomes irreversible.
- The findings point toward immunomodulatory therapy — targeting the TIM-3 pathway — as a potential intervention, echoing strategies already showing early promise in SFTS with drugs like ruxolitinib and tocilizumab.
Severe fever with thrombocytopenia syndrome arrives by tick bite and can kill nearly half the people it infects, triggering bleeding, organ failure, and neurological collapse. Since its discovery in China in 2009, SFTS has spread across Asia with no targeted treatment. Clinicians have long recognized the disease as a story of immune chaos — cytokine storms, exhausted T cells — but the behavior of natural killer cells, the body's first responders against viral invaders, remained poorly mapped. A new study suggests those cells may be part of the catastrophe.
Researchers compared blood samples from SFTS patients who recovered with those who died, using single-cell RNA sequencing and flow cytometry. They found that NK cells expressing a surface protein called TIM-3 were dramatically elevated in fatal cases — present on nearly 95 percent of circulating NK cells in deceased patients versus 74.5 percent in survivors. These TIM-3-positive cells were hyperactivated, saturated with cytotoxic molecules like granzyme B and perforin, and primed to destroy. As patients recovered, TIM-3 expression fell over two weeks, suggesting the immune system was finally stepping back from overdrive.
To test whether TIM-3 was driving this excess, the team treated patient-derived NK cells with an anti-TIM-3 antibody. The intervention reduced cytotoxic protein production, dampened interferon-gamma, and lowered multiple inflammatory cytokines. Unlike its role in some cancers — where TIM-3 acts as an inhibitory checkpoint — in SFTS it appeared to function as an accelerator, pushing NK cells toward greater destruction and inflammation.
The study also identified Galectin-9, a protein that binds TIM-3 and amplifies NK cell activation, as a clinically useful biomarker. Both soluble TIM-3 and Galectin-9 were significantly elevated in patients who died. When validated in an independent cohort of 104 patients from a separate hospital, Galectin-9 proved a robust predictor of 28-day mortality — offering clinicians a way to identify the most vulnerable patients early, before multi-organ failure forecloses intervention.
The findings carry broader implications. Vigorous immune response is not always protective; in SFTS, the immune system appears to overshoot, creating a self-amplifying cycle of NK cell hyperactivation that harms the host alongside the virus — a pattern echoed in severe COVID-19. The TIM-3 pathway now stands as a plausible therapeutic target, potentially complementing immunomodulatory drugs already showing early promise in SFTS. The initial cohort was small and the mechanistic link between TIM-3 signaling and NK cell behavior remains correlational rather than proven causal, but the work fills a meaningful gap — and in a disease still spreading across Asia, early risk stratification and new therapeutic footholds may prove decisive.
Severe fever with thrombocytopenia syndrome kills between one in eight and one in two people who contract it. The virus arrives by tick bite, spreads through blood and bodily fluids, and triggers a cascade of organ failure—bleeding, clotting disorders, kidney collapse, brain dysfunction. Since its discovery in China in 2009, SFTS has appeared across Asia. Treatment remains largely supportive. Doctors have long known the disease involves immune chaos: cytokine storms, exhausted T cells, broken antibody responses. But a crucial piece of the immune puzzle has been missing. Natural killer cells—the body's frontline defenders against viruses—have remained poorly understood in SFTS. A new study, published in PLOS Neglected Tropical Diseases, reveals they may be doing more harm than good.
Researchers analyzed blood samples from SFTS patients using single-cell RNA sequencing and flow cytometry, comparing those who recovered with those who died. They found that natural killer cells expressing a protein called TIM-3 were dramatically elevated in fatal cases. These TIM-3-positive NK cells were hyperactivated, loaded with cytotoxic weapons—granzyme B, perforin—and primed to kill. The more TIM-3 on NK cells, the worse the outcome. In deceased patients, 94.7 percent of circulating NK cells carried TIM-3, compared to 74.5 percent in those who survived. The pattern held even as patients recovered: TIM-3 expression dropped over two weeks, suggesting the immune system was finally downshifting from overdrive.
The researchers then asked whether blocking TIM-3 would calm this excessive activation. They isolated NK cells from SFTS patients and treated them with an anti-TIM-3 antibody. The results were striking. Blocking TIM-3 reduced granzyme B and perforin production, dampened interferon-gamma secretion, and lowered multiple inflammatory cytokines. TIM-3 was not acting as a brake on NK cells, as it does in some cancers and chronic infections. Instead, it was functioning as an accelerator—a signal that told NK cells to attack harder and produce more inflammatory molecules. In SFTS, this hyperactivation appeared to be part of the problem, not the solution.
The study also identified a second biomarker: Galectin-9, a protein that binds to TIM-3 and amplifies NK cell activation. Serum levels of both soluble TIM-3 and Galectin-9 were significantly higher in patients who died compared to those who recovered. When the researchers tested these markers in an independent validation cohort of 104 SFTS patients from another hospital, Galectin-9 proved particularly valuable. Patients with high serum Galectin-9 had substantially worse 28-day survival. The protein emerged as a robust early warning signal—a way to identify high-risk patients within hours of admission, before organ failure becomes irreversible.
The findings reframe how clinicians should think about NK cell activation in acute viral infection. Vigorous immune response is not always protective. In SFTS, the immune system appears to overshoot, generating a self-amplifying cycle of NK cell hyperactivation and inflammatory cytokine release that damages the host as much as the virus does. This mirrors observations in COVID-19 and other severe viral infections, where excessive NK cell activation correlates with worse outcomes. The discovery opens a therapeutic avenue: blocking the TIM-3 pathway could theoretically curb this runaway immune response without crippling antiviral defense. Early immunomodulatory drugs like ruxolitinib and tocilizumab have already shown promise in SFTS by dampening inflammatory signaling. A TIM-3-targeted approach might offer another tool.
The study has limitations. The initial cohort was small—only 21 SFTS patients, with just four deaths—and came from a single hospital. The validation cohort was larger but still modest. The researchers could not definitively prove that TIM-3 signaling causes NK cell hyperactivation; they showed correlation and functional association, not causation. Animal models and detailed mechanistic studies will be needed to fully understand how TIM-3 drives NK cell behavior in SFTS. Longitudinal sampling at multiple timepoints would strengthen the trajectory analyses. Despite these constraints, the work fills a critical gap in understanding SFTS immunopathology and provides clinicians with a new biomarker for early risk stratification. As SFTS spreads across Asia and the threat of spillover to new regions remains real, tools to identify doomed patients early—and potential targets to modulate their immune response—could save lives.
Citas Notables
TIM-3 expression on NK cells correlates with enhanced cytotoxicity and fatal outcomes, suggesting excessive immune activation contributes to disease pathology rather than protection.— Study findings
Serum Galectin-9 remained significantly associated with mortality after adjustment for age, sex, and comorbidity index, whereas soluble TIM-3 showed no significant association with survival.— Cox regression analysis results
La Conversación del Hearth Otra perspectiva de la historia
Why does TIM-3 on NK cells seem to make things worse in SFTS when it's usually thought of as a checkpoint that restrains immune cells?
That's the puzzle. In chronic infections and cancers, TIM-3 typically marks exhausted cells—cells that have given up fighting. But in acute SFTS, TIM-3 appears to mark hyperactivated cells. The virus is new, the infection is acute, and the NK cells are ramped up to maximum. TIM-3 in this context seems to amplify that activation rather than suppress it. Context matters enormously.
So blocking TIM-3 actually calmed the NK cells down in your experiments. That's counterintuitive if TIM-3 is supposed to be inhibitory.
Exactly. When we blocked TIM-3 with antibodies, we saw less granzyme B, less perforin, less interferon-gamma. The cells were less lethal. That tells us TIM-3 is functioning as an activating signal here, not a silencing one. It's like TIM-3 is saying "go harder," not "stand down."
And Galectin-9, the ligand that binds TIM-3—that was even more predictive of death than TIM-3 itself. Why might that be?
Galectin-9 is the fuel for this system. When Galectin-9 engages TIM-3, it amplifies NK cell killing and cytokine production. High serum Galectin-9 means the TIM-3 axis is running hot. It's a more direct measure of the pathological activation state. In our validation cohort, patients with high Galectin-9 had significantly worse survival.
The patients who died had faster disease progression—shorter hospital stays. Does that mean the biomarker would catch them in time to intervene?
That's the hope. If Galectin-9 can be measured within hours of admission, before multi-organ failure sets in, it could flag patients who need aggressive immunomodulation immediately. But we don't yet know if lowering Galectin-9 or blocking TIM-3 would actually improve survival. That requires clinical trials.
What happens to TIM-3 expression as patients recover? Does it just fade away?
Yes. In the four patients we followed longitudinally, TIM-3 on NK cells dropped significantly two weeks into recovery. The immune system was downshifting. That dynamic—the rise and fall—suggests TIM-3 is genuinely linked to the acute phase of disease, not just a bystander marker.